Therapeutic Approaches to the Challenge of Neuronal Ceroid Lipofuscinoses

Title: Therapeutic Approaches to the Challenge of Neuronal Ceroid Lipofuscinoses

Volume: 12 Issue: 6

Author(s): R. Kohan, I. A. Cismondi, A. M. Oller-Ramirez, N. Guelbert, V. Tapia Anzolini, G. Alonso, S. E. Mole, R. Dodelson de Kremer and I. Noher de Halac

Affiliation:

Keywords: Enzyme replacement, gene, immune, lysosomal storage diseases, Neuronal ceroid lipofuscinoses, pharmacological, stem cell, therapies, progressive loss of vision, decreasing cognitive and motor skills, dementia, blood brain barrier, neural stem cell replacement, molecular cascade of events, autofluorescence

Abstract: The Neuronal Ceroid Lipofuscinoses (NCLs) are lysosomal storage diseases (LSDs) affecting the central nervous system (CNS), with generally with recessive inheritance. They are characterized by pathological lipofuscin-like material accumulating in cells. The clinical phenotypes at all onset ages show progressive loss of vision, decreasing cognitive and motor skills, epileptic seizures and premature death, with dementia without visual loss prominent in the rarer adult forms. Eight causal genes, CLN10/CTSD, CLN1/PPT1, CLN2/TPP1, CLN3, CLN5, CLN6, CLN7/MFSD8, CLN8, with more than 269 mutations and 49 polymorphisms (http://www.ucl.ac.uk/ncl) have been described. Other NCL genes are hypothesized, including CLN4 and CLN9; CLCN6, CLCN7 and possibly SGSH are under study. Some therapeutic strategies applied to other LSDs with significant systemic involvement would not be effective in NCLs due to the necessity of passing the blood brain barrier to prevent the neurodegeneration, repair or restore the CNS functionality. There are therapies for the NCLs currently at preclinical stages and under phase 1 trials to establish safety in affected children. These approaches involve enzyme replacement, gene therapy, neural stem cell replacement, immune therapy and other pharmacological approaches. In the next decade, progress in the understanding of the natural history and the biochemical and molecular cascade of events relevant to the pathogenesis of these diseases in humans and animal models will be required to achieve significant therapeutic advances.

Cite this article as:

Kohan R., A. Cismondi I., M. Oller-Ramirez A., Guelbert N., Tapia Anzolini V., Alonso G., E. Mole S., Dodelson de Kremer R. and Noher de Halac I., Therapeutic Approaches to the Challenge of Neuronal Ceroid Lipofuscinoses, Current Pharmaceutical Biotechnology 2011; 12 (6) . https://dx.doi.org/10.2174/138920111795542633